profit from every $100 of sales.
$0$100
Day One Biopharmaceuticals
We have no price for Day One Biopharmaceuticals since 24 April 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$21.53+0.00% today
+189.4% since Oct 9, 25
1-year low $7.041-year high $21.53
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Day One Biopharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $158 million in 2025, with -$107 million of profit last year.
SalesProfit
Day One Biopharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Day One Biopharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Day One Biopharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 131 | 158 | |
| 0 | 0 | 126 | 141 | |
| -147 | -206 | -217 | -128 | |
| -146 | -206 | -215 | -124 | |
| -142 | -189 | -95 | -107 | |
| -2.17 | -2.37 | -1.02 | – | |
| – | – | 96.0% | 89.1% | |
| – | – | -165.7% | -80.8% | |
| – | – | -72.8% | -67.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 349 | 376 | 583 | 508 |
| Cash | 85 | 231 | 125 | 197 |
| Total debt | 1 | 0 | 3 | 3 |
| Total liabilities | 17 | 30 | 80 | 67 |
| 332 | 347 | 503 | 441 | |
| 65 | 80 | 93 | – | |
| -34.9% | -46.9% | -34.0% | -22.7% | |
| -42.8% | -54.5% | -19.0% | -24.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -110 | -147 | -78 | -104 | |
| 0 | 3 | 74 | 4 | |
| -110 | -150 | -152 | -108 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 27 | 39 | 48 | 44 |
Valuation
- –
- –
- –
- –
- 14.1×
- –
- –
- -4.8%
- -4.8%
- –
Profitability
- 89.1%
- -80.8%
- -67.8%
- –
- –
- –
- –
- –
- –
- –
Growth
- +20.6%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 883
Top 28%of 870
Bottom 19%of 985
What analysts expect
- Average price target
- $23.75
- Range
- $21.50 – $26.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.35 | -0.31 | −12.9% |
| Feb 24, 2026 | -0.20 | -0.17 | −17.6% |
| Nov 4, 2025 | -0.19 | -0.28 | +31.8% |
| Aug 5, 2025 | -0.29 | -0.35 | +17.1% |
| May 6, 2025 | -0.35 | -0.46 | +23.9% |
| Feb 25, 2025 | -0.69 | -0.35 | −97.1% |
| Oct 30, 2024 | 0.38 | -0.41 | +192.7% |
| Jul 30, 2024 | -0.05 | -0.67 | +92.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
55No pass
Philip Fisher
54No pass
Peter Lynch
2No pass
Joel Greenblatt
2No pass
Charlie Munger
42No pass
Terry Smith
48No pass
Questions about Day One Biopharmaceuticals
Is Day One Biopharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Day One Biopharmaceuticals AI analysis
What does Day One Biopharmaceuticals do?
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. It is in Biotechnology.
Does Day One Biopharmaceuticals pay a dividend?
No. Day One Biopharmaceuticals does not pay a dividend at the moment.
Who are Day One Biopharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Day One Biopharmaceuticals's.
Prices: daily closes to Apr 24, 2026. Fundamentals: company reports via invest-like data.